Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C).
The multicenter, randomized, double-blind, placebo-controlled TrIuMPH study assessed the safety, tolerability, and preliminary efficacy of EBX-102-02 in 122 patients with moderate to severe IBS-C and IBS with diarrhoea (IBS-D).
Patients were randomized two-to-one to receive either eight capsules of EBX-102-02 on each of day one and day seven, or a matched placebo, and were followed up for six weeks after the first dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze